

October 27, 2022



2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPICS-02
- MONARCH 3
- SOLO1

corners

• PAOLA-1

Lung Cancer


- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate-816
- NADIM II[†]
- IMpower010[‡]

GU/GI and Other Cancer

- NICHE-2*
- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- EXPLORER/PATHFINDER

*ESMO Presidential Symposium [†]WCLC 2022

How is HER2-low defined? Therapeutic Impact



CLINICAL QUESTION

TROPiCS-02

refractory HR+ breast cancer

Does sacituzumab govitecan provide benefit to patients with previously treated *HR+/HER2-* mBC?

Second interim analysis and post-hoc subgroup analysis in HER2-low and HER2 IHC0


On April 7, 2021, the Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic <u>triple-negative breast cancer (mTNBC)</u> who have received two or more prior systemic therapies, at least one of them for metastatic disease



KEY DATA

TROPiCS-02

Study Design: Randomized, multicenter, open-label phase III study



Primary endpoint: PFS (BICR)

Secondary endpoints: OS, ORR, DoR, CBR (by LIR and BICR), PRO, safety *Post hoc subgroup analysis:* evaluated efficacy in HER2-low and HER2 IHC0 subgroups

At the planned second interim analysis of OS, 390 events have occurred, and median duration of follow-up was 12.5 months

Data cutoff date: July 1, 2022

TROPiCS-02: Demographics

Sacituzumab govitecan for refractory HER+/HER2 neg breast cancer

Baseline characteristic	Sacituzumab Govitecan (n = 272)	Physician's Choice (n = 271)
Female, n (%)	270 (99)	268 (99)
Median age, yr (range) • <65 yr, n (%) • ≥65 yr, n (%)	57 (29-86) 199 (73) 73 (27)	55 (27-78) 204 (75) 67 (25)
Race/ethnicity, n (%) • White • Black • Asian • Other or not reported	184 (68) 8 (3) 11 (4) 69 (25)	178 (66) 13 (5) 5 (2) 75 (28)
ECOG PS, n (%) • 0 • 1	116 (43) 156 (57)	126 (46) 145 (54)
Visceral mets at baseline, n (%)	259 (95)	258 (95)
Liver mets, n (%)	229 (84)	237 (87)
De novo MBC, n (%)	78 (29)	60 (22)

Baseline characteristic	Sacituzumab Govitecan (n = 272)	Physician's Choice (n = 271)
Median time from MBC diagnosis to randomization, mo (range)	48.5 (1.2-243.8)	46.6 (3.0-248.8)
Prior CT in neo/adjuvant setting, n (%)	173 (64)	184 (68)
Prior ET use in MBC setting ≥6 mo, n (%)	235 (86)	234 (86)
Prior CDK4/6 inhibitor use, n (%) • ≤12 mo • >12 mo • Unknown	161 (59) 106 (39) 5 (2)	166 (61) 102 (38) 3 (1)
Median prior CT regimens* for mBC, n (range)	3 (0-8)	3 (1-5)

*In total, 9 patients received prior CT regimens in the metastatic setting outside the per protocol inclusion criteria of 2-4

• Of 543 patients in ITT population, 92% evaluable by IHC

Baseline characteristics comparable among HER2-low, HER2 IHCO, and ITT populations

ESMO 2022. Abstr LBA76. . ESMO 2022. Abstr 214MO.

PFS and OS in the ITT Population

	PFS by BICR Analysis	Sacituzumab Govitecan (n = 272)	Physician's Choice (n = 271)
	Median PFS, mo (95% CI) Stratified hazard ratio (95% CI) Stratified log-rank P value 	5.5 (4.2-7.0) 0.66 (0.5 0.0	•
	6-mo PFS, % (95% Cl)	46.1 (39.4-52.6)	30.3 (23.6-37.3)
	9-mo PFS, % (95% Cl)	32.5 (25.9-39.2)	17.3 (11.5-24.2)
>	12-mo PFS, % (95% CI)	21.3 (15.2-28.1)	7.1 (2.8-13.9)

Govitecan (n = 272)	Physician's Choice (n = 271)
191	199
•	11.2 (10.1 – 12.7) 0.65-0.96) .020
61 (55 – 66)	47 (41–53)
	(n = 272) 191 14.4 (13.0 – 15.7) 0.79 (0 0

Response Rates in the ITT Population

BICR Analysis	Sacituzumab Govitecan (n = 272)	Physician's Choice (n = 271)
ORR, n (%)	57 (21)	38 (14)
• Odds ratio (95% CI)	1.63 (1.03 –	2.56), <i>P</i> = 0.035
 Best overall response, n (%) CR PR SD SD ≥6 mo PD NE 	2 (1) 55 (20) 142 (52) 35 (13) 58 (21) 15 (6)	0 38 (14) 106 (39) 21 (8) 76 (28) 51 (19)
CBR,* n (%)	92 (34)	60 (22)
• Odds ratio (95% CI)	1.80 (1.23 – 2.63), <i>P</i> = 0.003	
Median DoR, mo (95% Cl)	8.1 (6.7-9.1)	5.6 (3.8-7.9)


KEY DATA

TROPiCS-02: Retrospective Analysis by HER2 Status

Of the 543 patients from the TROPiCS-02 ITT population, 92% had tumors that were HER2-evaluable by IHC

- 52% HER2-Low (*IHC1+, IHC2+ [ISH-negative/unverified]): N=283
- 40% HER2 IHC0: N=217
- 8% were excluded from the analysis due to missing HER2 IHC status: N=43 (SG, n=22; TPC, n=21)

Demographics and baseline characteristics between the HER2-Low, HER2 IHC0, and ITT populations were comparable



Response Rates

	HER2-Low*		HER2	IHC0
	SG (n = 149)	TPC (n=134)	SG (n = 101)	TPC (n=116)
ORR, n (%)	38 (26)	16 (12)	16 (16)	17 (15)
 Odds ratio (95% CI) 	2.52 (1.3	33-4.78)	1.10 (0.5	52-2.30)
 Best Overall Response, n (%) CR PR SD SD6mo PD 	2 (1) 36 (24) 73 (49) 18 (12) 29 (19)	0 16 (12) 61 (46) 10 (7) 36 (27)	0 16 (16) 56 (55) 15 (15) 23 (23)	0 17 (15) 39 (34) 8 (7) 38 (33)
• NE CBR,* n (%)	9 (6) 56 (38)	21 (16) 26 (19)	6 (6) 31 (31)	22 (19) 25 (22)
Odds ratio (95% CI)	2.50 (1.46-4.30)		1.61 (0.8	
Median DoR, mo (95% CI)	7.4 (5.8 – 8.9)	4.1 (2.8 – 6.1)	8.1 (4.1 – NE)	6.1 (2.8 – 8.3)

* HER2-Low defined as IHC1+, or IHC2+ and ISH-negative/unverified.



TROPiCS-02: Sacituzumab govitecan

- Sacituzumab govitecan provided a statistically significant PFS and OS benefit over physician choice chemotherapy (TPC) in ITT population with HR+/HER2- mBC previously treated with ET, CDK4/6 inhibitors, and ≥2 CT regimens for mets
 - 3.2-mo OS improvement (median 14.4 vs 11.2 mo; HR: 0.79; 95% CI: 0.65-0.96; *P* = 0.02)
 - ORR, CBR, and DoR also improved with sacituzumab govitecan vs TPC
- Outcomes in HER2-low and HER2 IHC0 HR+/HER2- mBC were consistent with overall population
- No new safety concerns

Sacituzumab govitecan demonstrated statistically significant and clinical benefit to patients with heavily pre-treated HR+ breast cancer regardless of HER2 IHC status: better for mOS than mPFS

(3 mo median OS improvement; HR 0.79, p=0.02)



COMPARISON

DESTINY-Breast04 vs TROPiCS-02: HER2-low

Cross-study Comparison

HER2-low	DESTIN	Y-Breast04	TROPi	CS-02
FDA approval	breast cancer patients who have metastatic setting or developed	HER2-low (IHC 1+ or IHC 2+/ISH-) received a prior chemotherapy in the disease recurrence during or within 6 g adjuvant chemotherapy	, , , ,	ave received two or more prior
Study Design	T-DXd	vs TPC	Sacituzumab govitecan	vs TPC
Inclusion Criteria	• ≥1 ET if HR+	I-) unresectable or metastatic BC he metastatic setting or recurrence ≤6 es eligible	 Metastatic or locally recurrent, ino <i>Post hoc subgroup analysis</i> in HER At least 1 ET, taxane, and CDK4/6 i 2-4 previous lines of CT for metast qualified as a prior line of CT if dise 	2-low and HER2 IHCO subgroups nhibitor in any setting ratic disease (neo/adjuvant therapy
Ν	331 HR+v	ve cohort 163	149	134
Median PFS, mo	10.1 HR 0.51 (0.4)	0-0.64) P<0.0001 5.4	6.4 HR 0.58 (0.42-0	0.79) <i>P</i> < 0.001 4.2
ORR, %	52.6	16.3	26	12
Median DoR, mo	10.7	6.8	7.4	4.1
Safety, Grade 3 TEAE	195 (53%)	116 (67%)	109 (74%)	73 (59%)
 PRO data, time to deterioration Global health status/QoL Pain symptoms Fatigue 	11.4 months 16.4 months 11.1 months	7.5 months 6.1 months 4.5 months	(In ITT population) 4.3 months 3.8 months 2.2 months	3.0 months 3.5 months 1.4 months

ASCO 2022. Abstr LBA03; ESMO 2022. Abstr 2170

ESMO 2022. Abstr 214MO.

2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPiCS-02
- MONARCH 3
- SOLO1

corners

• PAOLA-1

Lung Cancer

- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate-816
- NADIM II[†]
- IMpower010[‡]

GU/GI and Other Cancer

- NICHE-2*
- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- EXPLORER/PATHFINDER

*ESMO Presidential Symposium [†]WCLC 2022

CLINICAL QUESTION

MONARCH 3

1st-line HR+ HER2 neg

Does front-line abemaciclib in combination with a nonsteroidal aromatase inhibitor provide benefit for postmenopausal patients with HR+/HER2- advanced breast cancer?

Interim analysis

Abemaciclib is the first and only CDK4/6 inhibitor approved as a monotherapy in advanced breast cancer (ABC) and in combination with endocrine therapy (ET) for the adjuvant treatment of high-risk, HR+, HER2- early breast cancer




KEY DATA

MONARCH 3: Abemaciclib for 1st-line HR+ HER2 neg

Study Design: Randomized, multicenter, phase III study

Stratification by metastatic site (visceral, bone only, or other) and prior ET (AI, no ET, or other)

R 2:1



- postmenopausal
- >12 mo disease-free interval since (neo)adjuvant ET, if applicable

• ECOG PS ≤1

(N = 493)

Abemaciclib 150 mg po BID + Anastrozole* 1 mg po QD or Letrozole* 2.5 m (n=328)

Placebo PO BID + Anastrozole* 1 mg po QD or Letrozole* 2.5 mg po QD (n = 165)

*per physician's choice: 79.1% received letrozole 19.9% received anastrozole

Primary endpoint: Investigator-assessed PFS

Key secondary endpoints: Overall survival, response rates, safety

KEY DATA

MONARCH 3: Abemaciclib

Preplanned Final PFS Analysis

Data cutoff: 03 Nov 2017


	Abemaciclib + NSAI (n = 328)	Placebo + NSAI (n = 165)
Median PFS, mo	28.2	14.8
 HR (95% CI) <i>P</i> value 	0.540 (0.418-0.698) 0.000021	
Events, n	138	108

NSAI, nonsteroidal aromatase inhibitor

- Statistical significance reached at interim PFS analysis led to FDA approval
 - PFS prolonged by 13.4 months
- OS data were immature at final PFS data cutoff; 29.5% events observed across both arms

Updated PFS in ITT Population


Data cut: 02 Jul 2021



• With a median follow-up of 5.8 yrs (additional 3.6 yrs from final PFS analysis), efficacy is maintained

Pre-planned OS Interim Analysis 2

Data cut: 02 Jul 2021




*p-value did not reach threshold for statistical significance at this interim



MONARCH 3

Chemotherapy-Free Survival in the ITT Population



Chemotherapy-Free Survival defined as the time to the initiation of subsequent chemotherapy or death from any cause, whichever was earlier



MONARCH 3: Abemaciclib

- With an additional follow-up of 3.6 years from final PFS analysis, efficacy is maintained and provides a significant benefit for patients
 - HR (95% CI; P value): 0.518 (0.415-0.648) nominal p<0.0001*
- Abemaciclib plus a nonsteroidal aromatase inhibitor in patients with hormone receptor—positive/HER2negative advanced breast cancer showed a non-significant overall survival trend when compared to placebo with a NSAI at the second interim analysis
 - HR (95% CI; P value): 0.754 (0.584-0.974) p-value 0.0301
 - Median 12.6 month difference between treatment arms favoring abemaciclib
- No new safety concerns with prolonged exposure to abemaciclib

The addition of abemaciclib to a nonsteroidal aromatase inhibitor in the front line setting for patients with hormone receptor-positive/HER2negative advanced breast cancer provides benefit and delays the use of chemotherapy

Final OS data to come...



2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPiCS-02
- MONARCH 3
- SOLO1

corners

• PAOLA-1

Lung Cancer

- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate-816
- NADIM II[†]
- IMpower010[‡]

GU/GI and Other Cancer

- NICHE-2*
- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- EXPLORER/PATHFINDER

*ESMO Presidential Symposium [†]WCLC 2022



- On June 10, 2022, <u>Clovis Oncology, Inc.</u> voluntarily withdrew <u>Rubraca (rucaparib)</u> as a treatment of <u>BRCA-</u> <u>mutated ovarian cancer after two or more chemotherapies</u> based on OS data from the Phase III ARIEL4 study showing disappointing results (31.3% greater risk for death) for rucaparib compared with chemotherapy, and particularly in patients with platinum-resistant tumors.
- **On August 11, 2022**, <u>AstraZeneca</u> voluntarily withdrew <u>Lynparza (olaparib)</u> indication for the treatment of adult patients with deleterious or suspected deleterious germline <u>BRCA-mutated (gBRCAm) advanced ovarian cancer</u> who have been treated with <u>three or more prior lines of chemotherapy</u> based on the randomized Phase III SOLO3 study stating there is a "potential detrimental effect on the overall survival" (33% greater risk of death) for olaparib compared to the chemotherapy control arm.
- **On September 14, 2022**, <u>GSK</u> voluntarily withdrew <u>ZEJULA (niraparib)</u> indication for the treatment of adult patients with <u>advanced ovarian</u>, fallopian tube, or primary peritoneal cancer who have been treated with <u>3 or more prior chemotherapy regimens</u> and whose cancer is associated with <u>homologous recombination deficiency</u> (<u>HRD</u>) positive status "based on a totality of information from PARP inhibitors in the late line treatment setting" and on the single arm, uncontrolled QUADRA trial with no comparative overall survival information.



CLINICAL QUESTION SOLO1: 7-year follow-up

Does maintenance olaparib continue to provide benefit to patients with newly diagnosed advanced ovarian cancer and a BRCA mutation?

7-year follow-up

Olaparib is FDA approved:


- for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza
- in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary
 peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with
 homologous recombination deficiency (HRD)-positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or
 genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza
- and for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.



KEY DATA

SOLO1: 7-year follow-up

Study Design: Randomized, double-blind, phase III study



Primary endpoint: PFS (investigator assessed)

Key secondary endpoints: OS, TFST (time to first subsequent therapy or death), TSST (time to second subsequent therapy or death), Safety

*Upfront or interval attempt at optimal cytoreductive surgery for stage III disease and either biopsy and/or upfront or interval cytoreductive surgery for stage IV disease

⁺ Including patients with no evidence of disease

‡ Patients with evidence of disease at 2 years could continue to receive study treatment if, in the investigator's opinion, this was in the patient's best interest

Baseline Characteristics

Characteristic, n (%)	Olaparib (n = 260)	Placebo (n = 131)
FIGO stage • • V	220 (84.6) 40 (15.4)	105 (80.2) 26 (19.8)
BRCA mutation • BRCA1 • BRCA2 • BRCA1 + BRCA2	191 (73.5) 66 (25.4) 3 (1.2)	91 (69.5) 40 (30.5) 0
 Upfront cytoreductive surgery Residual macroscopic disease No residual macroscopic disease Unknown 	161 (61.9) 37 (23.0) 123 (76.4) 1 (0.6)	85 (64.9) 22 (25.9) 62 (72.9) 1 (1.2)
 Interval cytoreductive surgery Residual macroscopic disease No residual macroscopic disease 	94 (36.2) 18 (19.1) 76 (80.9)	43 (32.8) 7 (16.3) 36 (83.7)
No surgery	4 (1.5)	3 (2.3)
 Response after surgery/platinum-based chemotherapy Clinical CR (includes pts with no evidence of disease) Clinical PR 	213 (81.9) 47 (18.1)	107 (81.7) 24 (18.3)



SOLO1: 7-year follow-up

PFS Analysis


<i>Primary PFS Analysis</i> (data cutoff: 17 May 2018)	Olaparib (n-=260)	Placebo (n=131)
Events, n (%)	102 (39.2)	96 (73.3)
Median PFS, months	NR	13.8
3-year PFS rate, %	60.4	26.9
HR (95% CI) <i>, P</i> -value	0.30 (0.23 – 0.41), <i>P</i> < 0.001	

Updated PFS Analysis (data cutoff: 5 March 2020)	Olaparib (n-=260)	Placebo (n=131)
Events, n (%)	118 (45.4)	100 (76.3)
Median PFS, months	56.0	13.8
5-year PFS rate, %	48.3	20.5
HR (95% CI) <i>, P</i> -value	0.33 (0.25 – 0.43), <i>P</i> < 0.001	



SOLO1: 7-year follow-up

Overall Survival



OS	Olaparib (n-=260)	Placebo (n=131)
Events, n (%)	84 (32.3)	65 (49.6)
Median OS, months	NR	75.2
HR (95% CI) <i>P-</i> value	0.55 (0.40 – 0.76) <i>P</i> = 0.0004*	


* P<0.0001 required to declare statistical significance

 44.3% of patients in the placebo group received subsequent PARP inhibitor therapy, compared with 14.6% of patients in the olaparib group

KEY DATA


SOLO1: 7-year follow-up

TFST (time to first subsequent therapy or death)



TFST	Olaparib (n-=260)	Placebo (n=131)
Events, n (%)	135 (51.9)	98 (74.8)
Median PFS, months	64.0	15.1
HR (95% CI)	0.37 (0.28 – 0.48)	

TSST (time to second subsequent therapy or death)



TSST	Olaparib (n-=260)	Placebo (n=131)
Events, n (%)	110 (42.3)	80 (61.1)
Median PFS, months	93.2	40.7
HR (95% CI)	0.50 (0.37 – 0.67)	



SOLO1: 7-year follow-up

- Clinically meaningful signal, although not significant improvement in OS with maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation
 - Median OS not yet reached
 - HR 0.55 (95% CI, 0.40 to 0.76; *P* = .0004 [*P* < .0001 required to declare statistical significance])
- At 7 yrs after diagnosis, 67.0% of olaparib pts versus 46.5% of placebo pts were alive, and 45.3% versus 20.6%, respectively, were alive and had not received a first subsequent treatment
- No new safety signals observed during long-term follow-up

For newly diagnosed advanced ovarian cancer and a BRCA mutation, olaparib continues to provide long term benefit far beyond the 2-year treatment cap and should be considered for eligible patients

BRCA testing is important to identify patients



2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPiCS-02
- MONARCH 3
- SOLO1

corners

• PAOLA-1

Lung Cancer

- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate-816
- NADIM II[†]
- IMpower010[‡]

GU/GI and Other Cancer

- NICHE-2*
- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- EXPLORER/PATHFINDER

*ESMO Presidential Symposium [†]WCLC 2022

PAOLA-1

Does maintenance olaparib plus bevacizumab benefit previously treated patients with newly diagnosed advanced ovarian cancer?

Final Overall Survival Analysis

Olaparib is FDA approved:


CLINICAL QUESTION

- for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza
- in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza
- and for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.



PAOLA-1

Study Design: Randomized, placebo-controlled, phase III study



Primary endpoint: PFS (investigator assessed, RECIST v1.1)

Key secondary endpoints: PFS2, OS (planned for 3 years after the primart PFS analysis or 60% data maturity

*Patients with other epithelial non-mucinous ovarian cancer were eligible if they had a gBRCAm; †Patients must have received ≥4 and ≤9 cycles of platinum-based chemotherapy; ‡Patients must have received ≥3 cycles of bevacizumab with the last 3 cycles of chemotherapy, apart from patients undergoing interval surgery who were permitted to receive only 2 cycles of bevacizumab with the last 3 cycles of chemotherapy, apart from patients undergoing interval surgery who were permitted to receive only 2 cycles of bevacizumab with the last 3 cycles of chemotherapy; §Bevacizumab 15 mg/kg every 3 weeks for a total of 15 months, including when administered with chemotherapy; ¶According to timing of surgery and NED/CR/PR.

Final OS Date Cutoff: 22 March 2022

Baseline Characteristics


Characteristic	Olaparib + Bev (n = 537)	Placebo + Bev (n = 269)
Median age, yr (range)	61 (32-87)	60 (26-85)
FIGO stage, n (%) • • \/	378 (70) 159 (30)	186 (69) 83 (31)
 HRD status,* n (%) HRD positive tBRCAm HRD positive excluding tBRCAm HRD negative/HRD unknown HRD negative 	255 (47) 157 (29) 97 (18) 282 (53) 192 (36)	132 (49) 80 (30) 55 (20) 137 (51) 85 (32)

*BRCAm status by central labs and HRD status by Myriad myChoice HRD Plus; patients in tBRCAm and HRD positive excluding tBRCAm subgroups do not equal the total number of patients in the HRD-positive subgroup because of different testing methods. tBRCAm, tumour BRCAm.

Characteristic, n (%)	Olaparib + Bev (n = 535)	Placebo + Bev (n = 269)
History of cytoreductive surgery		
Upfront surgery	271 (50)	138 (51)
 No residual macroscopic disease 	160 (59)	85 (62)
 Residual macroscopic disease 	111 (41)	53 (38)
Interval cytoreductive surgery	228 (42)	110 (41)
 No residual macroscopic disease 	163 (71)	75 (68)
 Residual macroscopic disease 	65 (29)	35 (32)
No surgery	38 (7)	21 (8)
Response after surgery/PBC		
• NED	290 (54)	141 (52)
• CR	106 (20)	53 (20)
• PR	141 (26)	75 (28)

PAOLA-1: Bev +/- Olaparib

Overall Survival: ITT population




OS (ITT population)	Olaparib + bevacizumab (n-=537)	Placebo + bevacizumab (n=269)
Events, n (%)	288 (53.6)	158 (58.7)
Median OS, months	56.5	51.6
5-year OS rate, %	47.3	41.5
HR (95% CI) <i>P-</i> value	0.92 (0.76 – 0.76) <i>P</i> = 0.4118	

Patients receiving a PARP inhibitor during any subsequent treatment:

- Olaparib + bevacizumab: 19.6% (105/537)
- Placebo + bevacizumab: 45.7% (123/269)

PAOLA-1: Bev +/- Olaparib

Overall Survival: HRD-positive subgroup




OS (HRD-positive)	Olaparib + bevacizumab (n=255)	Placebo + bevacizumab (n=132)
Events, n (%)	93 (36.5)	69 (52.3)
Median OS, months	75.2	57.3
5-year OS rate, %	65.5	48.4
HR (95% CI)	0.62 (0.45 – 0.85)	

Patients receiving a PARP inhibitor during any subsequent treatment:

- Olaparib + bevacizumab: 17.3% (44/255)
- Placebo + bevacizumab: 50.8% (67/132)

PAOLA-1: Bev +/- Olaparib

Updated PFS: HRD-positive subgroup




Updated PFS (HRD-positive)	Olaparib + bevacizumab (n=255)	Placebo + bevacizumab (n=132)		
Events, n (%)	136 (53.3)	104 (78.8)		
Median OS, months	46.8	17.6		
5-year OS rate, %	46.1	19.2		
HR (95% CI)	0.41 (0.32 – 0.54)			

KEY DATA

PAOLA-1: Bev +/- Olaparib

OS subgroup analysis: by BRCAm and HRD status



ESMO 2022. Abstr LBA29.

PAOLA-1: Bev +/- Olaparib

AEs of Special Interest in Final OS Analysis

	Primary PF 22 Mare	-	Final PFS2 Analysis 22 March 2020		Final OS Analysis 22 March 2022	
AEs, n (%)	Olaparib + Bev (n = 535)	Placebo + Bev (n = 267)	Olaparib + Bev (n = 535)	Placebo + Bev (n = 267)	Olaparib + Bev (n = 535)	Placebo + Bev (n = 267)
MDS/AML/AA	6 (1.1)	1 (0.4)	7 (1.3)	4 (1.5)	9 (1.7)	6 (2.2)
New primary malignancies*	7 (1.3)	3 (1.1)	13 (2.4)	5 (1.9)	22 (4.1)	8 (3.0)
Pneumonitis/ILD/bronchiolitis+	6 (1.1)	0 (0.0)	6 (1.1)	0 (0.0)	7 (1.3)	2 (0.7)

All patients had discontinued treatment at PFS2 DCO

*New primary malignancies were: 1 plasma cell myeloma, 2 basal cell carcinoma, 11 breast cancer, 1 bronchial carcinoma, 1 colon cancer, 1 glioblastoma, 1 malignant neoplasm, 1 pancreatic carcinoma, 2 squamous cell carcinoma, and 1 ureteric cancer in the olaparib arm; and 1 papillary thyroid cancer, 4 breast cancer, 1 diffuse large B-cell lymphoma, 1 malignant lung neoplasm, and 1 malignant neoplasm in the placebo arm

[†]Pneumonitis/ILD/bronchiolitis events were: 1 bronchiolitis, 1 pneumonia, 1 acute respiratory distress syndrome, 2 interstitial lung disease, and 2 pneumonitis in the olaparib arm; and 1 corona virus infection and 1 pneumonitis case in the placebo arm.



PAOLA-1: Bev +/- Olaparib

- At 5-yr follow-up, for patients with newly diagnosed advanced ovarian cancer who had received first-line standard-of-care treatment including bevacizumab, the addition of maintenance olaparib to bevacizumab provided a clinically meaningful OS benefit in the HRD positive population regardless of BRCAm status
 - *HRD-positive*: 65.5% vs 48.4%; HR 0.62, 95% CI 0.45 0.85
 - *HRD-positive excluding BRCAm*: 54.7% vs 44.2%; HR 0.71, 95% CI 0.45 1.13
- No OS difference in the ITT population or HRD-negative group
- No new safety signals with follow-up

The addition of olaparib to bevacizumab should be considered as a standard of care for HRD-positive patients with newly diagnosed advanced ovarian cancer who had received first-line standard-of-care treatment including bevacizumab

Highlights the importance of precision medicine and biomarker testing to guide treatment decisions, and HRD testing is evolving



2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPiCS-02
- MONARCH 3
- SOLO1
- PAOLA-1

Lung Cancer

- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate-816
- NADIM II[†]
- IMpower010[‡]

GU/GI and Other Cancer

- NICHE-2*
- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- EXPLORER/PATHFINDER

*ESMO Presidential Symposium ⁺ WCLC 2022



Does sotorasib provide benefit for patients previously treated for advanced NSCLC with KRAS G12C mutation?

On May 28, 2021, the Food and Drug Administration granted accelerated approval to sotorasib (Lumakras™), a RAS GTPase family inhibitor based on CodeBreaK 100, for adult patients with KRAS G12C -mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.




KEY DATA

CodeBreaK 200

Study Design: Randomized, double-blind phase III study

Secondary endpoints: OS⁺, ORR, DOR, TTR, DCR, safety/tolerability, PRO



CodeBreaK 100: phase I/II trial


- ORR of 41%
- mPFS of 6.3 mo
- mOS of 12.5 mo

- Patients with locally ٠ advanced/unresectable or metastatic **KRAS G12C-mutated NSCLC**
- ≥ 1 prior treatment including platinum-٠ based chemotherapy and checkpoint inhibitor*
- no active brain metastases ٠

Primary endpoint: PFS by BICR

ECOG PS 0/1 ٠

(N = 345)



Per regulatory guidance, protocol was amended to reduce planned enrolment from 650 to ~330 patients, and crossover from docetaxel to sotorasib was permitted.

Enrollment period: June 4, 2020 to April 26, 2021 Data cutoff: August 2, 2022

*Treatment with chemotherapy and checkpoint inhibitor could be concurrent or sequential; patients with medical contraindication to these therapies could be included with approval. ⁺Analysis of OS planned if PFS was found to be statistically significant and when at least 198 OS events have been reached.

© 2022 Cornerstone Specialty Network. All rights reserved.

ESMO 2022. Abstr LBA10.

Baseline Characteristics


Characteristic	Sotorasib (n = 171)	Docetaxel (n = 174)
Median age, yr (range)	64.0 (32-88)	64.0 (35-87)
Female, n (%)	62 (36.3)	79 (45.4)
North America/Europe/Other,* %	11.7/73.7/14.6	12.6/72.4/14.9
Current or former smoker, n (%)	166 (97.1)	166 (95.4)
ECOG PS 1, n (%)	112 (65.5)	115 (66.1)
History of CNS involvement, n (%)	58 (33.9)	60 (34.5)
Liver metastasis, n (%)	30 (17.5)	35 (20.1)
Prior lines of therapy for advanced disease, n (%) 1 2 >2 	77 (45.0) 65 (38.0) 29 (17.0)	78 (44.8) 69 (39.7) 27 (15.5)
PD-L1 expression, n (%) <1% ≥1 to <50% ≥50% 	57 (33.3) 46 (26.9) 60 (35.1)	55 (31.6) 70 (40.2) 40 (23.0)

*Other includes Asia, Australia, South America.



CodeBreaK 200

Primary Endpoint: PFS by BICR




*PFS rates estimated using Kaplan-Meier method; ITT population.

⁺HR and 95% CIs estimated using a stratified Cox proportional hazards model.

[‡]P-value calculated using a stratified log-rank test. §Medians estimated using Kaplan-Meier method; 95% CIs estimated using the method by Klein and Moeschberger with log-log transformation

CodeBreaK 200

Overall Survival



OS rates estimated using Kaplan-Meier method; ITT population.


[†]HR and 95% CIs estimated using a stratified Cox proportional hazards model

‡ P-value calculated using a stratified log-rank test.

§Medians estimated using Kaplan-Meier method; 95% CIs estimated using the method by Klein and Moeschberger with log-log transformation.


**Patients (16.4% in sotorasib arm, 5.2% in docetaxel arm) were treated beyond progression

Tumor Response by BICR



ORR: Overall response rate; DCR: Disease control rate; DpR: Depth of response





*DOR and TTR calculated only for patients who achieved a confirmed best overall response of PR or CR; ITT population. †Number of responders. ‡Medians and 95% CIs estimated using Kaplan-Meier method DoR, duration of response; PFS, progression-free survival; TTR, time to response.

CodeBreaK 200

Safety Summary


Parameter	Sotorasib (n = 169)	Docetaxel (n = 151)
TEAEs, n (%) • Grade ≥3	166 (98.2) 121 (71.6)	148 (98.0) 91 (60.3)
TRAEs, n (%)	119 (70.4)	130 (86.1)
• Grade ≥3	56 (33.1)	61 (40.4)
Serious	18 (10.7)	34 (22.5)
 Leading to dose interruption* 	60 (35.5)	23 (15.2)
 Lading to dose reduction[†] 	26 (15.4)	40 (26.5)
 Leading to dose discontinuation[‡] 	16 (9.5)	17 (11.3)
Fatal TRAEs, n (%) [§]	1 (0.6)	2 (1.3)
Median duration of treatment, weeks (range)	20 (0.4-101)	12 (3-101)

*For sotorasib, diarrhoea (n=22), increased ALT (n=9), and AST (n=7), and for docetaxel, fatigue and pneumonia (both n=3), hypersensitivity and myalgia (both n=2) were the most common.

⁺For sotorasib, diarrhoea (n=14), increased ALT (n=6), and AST (n=3), and for docetaxel, neutropenia (n=7), fatigue (n=6), febrile neutropenia, peripheral neuropathy, and asthenia (n=4 each) were the most common.

‡For sotorasib, increased ALT (n=6), blood bilirubin (n=4), AST and blood alkaline phosphatase (both n=2), and drug-induced liver injury (n=2), and for docetaxel, fatigue (n=3) and febrile neutropenia (n=2) were most common.

§Fatal TRAEs were observed in 1 patient in the sotorasib group (interstitial lung disease) and 2 patients in the docetaxel group (ileus and multiorgan failure)





CodeBreaK 200

- Modest but significant PFS improvement with sotorasib vs docetaxel in previously treated patients with *KRAS* G12C-mutated advanced NSCLC
 - Median PFS: 5.6 vs 4.5 mo (HR: 0.66; *P* = 0.002)
 - 12-mo PFS: 24.8% vs 10.1%
 - Benefit similar across most subgroups
- ORR, DCR, TTR, and DoR improved for sotorasib vs docetaxel but no difference in OS (not powered)
- Acceptable safety profile; fewer grade ≥3 TRAEs with sotorasib vs docetaxel
- Patient-reported outcomes more favorable for sotorasib vs docetaxel

Sotorasib continues to show benefit in pre-treated patients with KRAS G12C mutated NSCLC and provides an important targeted treatment option

Highlights importance of biomarker testing for all patients with advanced disease



2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPiCS-02
- MONARCH 3
- SOLO1
- PAOLA-1

Lung Cancer

- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate 816
- NADIM II[‡]
- IMPower010[‡]

GU/GI and Other Cancer

- NICHE-2*
- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- EXPLORER/PATHFINDER


* ESMO Presidential Symposium ⁺ WCLC 2022



Does atezolizumab in the 1L setting improve outcomes for patients with NSCLC with poor performance status and are ineligible for a platinum-containing regimen?



Study Design: global, multicenter, open-label, randomized, controlled phase III study



Primary endpoint: OS

KEY DATA

IPSOS

Secondary endpoints: OS rates at 6, 12, 18 and 24 months, PFS, ORR, DOR, OS and PFS in PD-L1 positive subgroups **Other endpoints**: PROs, safety, exploratory biomarker analyses

Baseline Characteristics

Characteristic	Atezolizumab (n=301)	Chemotherapy (n=151)	Characteristic	Atezolizumab (n=301)	Chemotherapy (n=151)
Median age, yr (range) <70 yrs, n (%) 70-79 yrs, n (%) ≤80 yrs, n (%)	75.0 (33, 94) 80 (26.5) 125 (41.4) 97 (32.1)	75.0 (37, 89) 43 (28.5) 65 (43.0) 43 (28.5)	Brain metastases, n (%) Yes No Missing	27 (8.9) 273 (90.4) 2 (0.7)	13 (8.6) 137 (90.7) 1 (0.7)
ECOG PS, n (%) 0/1 2 3	56 (18.5) 228 (75.5) 18 (6.0)	19 (12.6) 116 (76.8) 16 (10.6)	Smoking status, n (%) Previous Current Never	209 (69.2) 58 (19.2) 35 (11.6)	103 (68.2) 28 (18.5) 20 (13.2)
Sex, male, n (%)	220 (72.8)	108 (71.5)	DD 11 overacion loval		
Race, n (%)* White Asian	203 (67.2) 75 (24.8)	95 (62.9) 38 (25.2)	PD-L1 expression level, n (%)*** TC <1% TC ≥1%	151 (50.0) 127 (42.1)	61 (40.4) 78 (51.7)
Histology, n (%)** Non-squamous Squamous	173 (57.3) 129 (42.7)	87 (57.6) 64 (42.4)	TC 1-49% TC ≥50% Unknown	77 (25.5) 50 (16.6) 24 (7.9)	53 (35.1) 25 (16.6) 12 (7.9)

Clinical cutoff: 30 Apr 2022.

*In the atezolizumab arm, 12 patients were American Indian or Alaska Native, 2 Black or African American, 6 multiple races, and 4 unknown. In the chemotherapy arm, 9 patients were American Indian or Alaska Native, 1 Black or African American, 6 multiple races, and 2 unknown.


**Per electronic case report form.

***By SP263 IHC assay.



IPSOS

Primary Endpoint: OS



KEY DATA

OS by Subgroup


	Atezo	Chemo				Atezo	Chemo		
Subgroup	<u>n</u>	<u>n</u> 151		<u>HR (95% CI)</u>	Subgroup	<u>n</u>	<u>n</u>		<u>HR (95% CI)</u>
All patients	<u>n</u> 302	151		0.78 (0.63, 0.97) ^a	All patients	302	151	I ♠	0.78 (0.63, 0.97) ^a
Age					Stage				
<70 y	80	43	⊢♦÷	0.75 (0.49, 1.14)	IIIB	41	21	⊢ ◆ ∔	0.69 (0.39, 1.24)
70-79 y	125	65	HI I	0.68 (0.49, 0.94)	IV	261	130	+	0.81 (0.64, 1.02)
≥80 y	97	43		0.97 (0.66, 1.44)	Brain metastases				
Sex					Yes	27	13	⊢	0.85 (0.40, 1.80)
Male	220	108	⊢ ♠-{	0.76 (0.59, 0.98)	No	273	137	H A	0.78 (0.62, 0.98)
Female	82	43	⊢ ↓	0.86 (0.58, 1.27)	Liver metastases				
Race					Yes	44	26		0.94 (0.55, 1.59)
White	203	95	н	0.86 (0.67, 1.11)	No	258	125	H.	0.77 (0.61, 0.98)
Asian	75	38	⊢ e ∔i	0.74 (0.46, 1.20)	Number of metasta	atic sites			
ECOG PS					<3	124	73	⊢ ↓	0.74 (0.53, 1.03)
0/1	56	19	⊢ ↓	0.64 (0.36, 1.13)	≥3	141	59	⊨ ◆ ∔	0.78 (0.56, 1.07)
2	228	116	н	0.86 (0.67, 1.10)	PD-L1 expression	level ^b			
3	18	16	⊢ → i →	0.74 (0.35, 1.57)	TC <1%	151	61	н	0.81 (0.58. 1.11)
Tobacco use history					TC ≥1%	127	78	⊢ ↓	0.84 (0.62, 1.15)
Previous	209	103		0.83 (0.64, 1.08)	TC 1-49%	77	53	⊨ ∳	0.84 (0.57, 1.22)
Current	58	28	⊢ ↓	0.65 (0.40, 1.07)	TC ≥50%	50	25	⊢	0.87 (0.50, 1.52)
Never	35	20	⊢ ♦ ¦-1	0.70 (0.37, 1.35)	Unknown	24	12	—	0.49 (0.21, 1.14)
Histology							0.1	1	10
Non-squamous	173	87	⊢ ♦-j	0.77 (0.58, 1.03)			←	HR	→
Squamous	129	64 .	⊢♦÷	0.80 (0.58, 1.12)			Atezolizun	nab better Chemo	therapy better
		0.1	1	10					
			HR	_					
		Atezolizum	ab better Chemo	therapy better					

^a Stratified for all patients; unstratified for all other subgroups. ^b Per SP263 IHC assay

KEY DATA

IPSOS

PFS



ORR and DOR

	Atezolizumab (n=302)	Chemotherapy (n=151)
ORR, n (%), (95% Cl)	51 (16.9) (12.8, 21.6)	12 (7.9) (4.2, 13.5)
CR, n (%)	4 (1.3)	0 (0)
PR, n (%)	47 (15.6)	12 (7.9)
Stable disease, n (%)	122 (40.4)	73 (48.3)
Disease control rate, n (%)	173 (57.3)	85 (56.3)
Progressive disease, n (%)	67 (22.2)	36 (23.8)
Non-evaluable, n (%)	14 (4.6)	12 (7.9)
Missing, n (%)	48 (15.9)	18 (11.9)
Median DOR, months (95% CI)	14.0 (8.1, 20.3)	7.8 (4.8, 9.7)

Safety Summary

	Atezolizumab (n=300)	Gemcitabine (n=63)	Vinorelbine (n=84)
Median treatment duration, months (range)	3.5 (0-51)	2.3 (0-13)	1.8 (0.21)
Median number of cycles initiated (range)	6.0 (1-73)	4.0 (1-19)	3.0 (1-31)

	Atezolizumab (n=300)	Chemotherapy (n=147)
All-grade AE, n (%)	275 (91.7)	143 (97.3)
Treatment-related AE	171 (57.0)	118 (80.3)
Grade 3-4 AE, n (%)	136 (45.3)	71 (48.3)
Treatment-related Grade 3-4 AE	49 (16.3)	49 (33.3)
Serious AE, n (%)	146 (48.2)	53 (36.1)
Treatment-related SAE	35 (11.7)	23 (15.6)
Grade 5 AE, n (%)	35 (11.7)	13 (8.8)
Treatment-related Grade 5 AE	3 (1.0)	4 (2.7)
AE leading to discontinuation of study drug, n (%)	39 (13.0)	20 (13.6)
AE leading to modification/interruption of study drug, n (%)	96 (32.0)	71 (48.3)

IPSOS

- In this poor-prognosis difficult to treat population, atezolizumab in the 1L setting improved OS compared to single agent chemotherapy
 - 2-year OS rate nearly doubled with atezolizumab (24.3% vs 12.4%)
- ORR was better with atezolizumab with durable responses (14 vs 7.8 months)
- No new safety signals with fewer treatment related Grade 3/4 AEs in the atezolizumab arm compared to the chemotherapy arm (16.3% vs 33.3%, respectively)
 - Atezolizumab stabilized health-related QOL functions and significantly improved time to deterioration of chest pain (HR: 0.51) vs chemotherapy

Atezolizumab in the IL setting improves outcomes for patients with poor prognosis NSCLC and provides an alternative treatment option for those ineligible to receive platinum-doublet chemotherapy



2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPiCS-02
- MONARCH 3
- SOLO1
- PAOLA-1

Lung Cancer

- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate 816
- NADIM II[†]
- IMPower010[‡]

GU/GI and Other Cancer

- NICHE-2*
- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- EXPLORER/PATHFINDER

* ESMO Presidential Symposium ⁺ WCLC 2022



Does trastuzumab deruxtecan provide benefit for patients with HER2 mutant metastatic non-small cell lung cancer?

Interim Analysis

On August 11, 2022, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. This is the first drug approved for HER2-mutant NSCLC.



KEY DATA

٠

٠


•

•

٠

DESTINY-Lung02

Study Design: randomized, multicenter, International, 2-arm, noncomparative phase II trial



Primary endpoint: confirmed ORR by BICR

Secondary endpoints: ORR by investigator, DoR,* DCR,* PFS,* OS,* PK, PROs, safety and tolerability

Data cutoff: Mar 24, 2022

Median follow-up: 5.54 months

(n = 52)

(n = 28)

the protocol to assess those patients with ≥3 post-baseline assessments at data cutoff

(assessments performed every 6 weeks)

Patients, investigators, and site staff are blinded to the dose level

Response by BCIR

Response	T-DXd 5.4 mg/kg (n = 52)	T-DXd 6.4 mg/kg (n = 28)
Confirmed ORR,* n (%; 95% Cl)	28 (53.8 ; 39.5-67.8)	12 (42.9 ; 24.5-62.8)
Best overall response, n (%) CR PR SD PD NE [†]	1 (1.9) 27 (51.9) 19 (36.5) 2 (3.8) 3 (5.8)	1 (3.6) 11 (39.3) 14 (50.0) 1 (3.6) 1 (3.6)
DCR [‡] , n (%; 95% Cl)	47 (90.4; 79.0-96.8)	26 (92.9; 76.5-99.1)
Median DoR, mo (95% CI)	NE (4.2-NE)	5.9 (2.8-NE)
Median TTIR, mo (range)	1.4 (1.2-5.8)	1.4 (1.2-3.0)
Median follow-up, mo (range)	5.6 (1.1-11.7)	5.4 (0.6-12.1)

Data cutoff: Mar 24, 2022.

*Proportion of patients with confirmed CR or PR assessed by BICR per RECIST v1.1.

⁺3 patients were not evaluable at 5.4 mg/kg (1 patient never received treatment due to Covid; 2 patients discontinued before first tumor assessment); 1 not evaluable at 6.4 mg/kg (discontinued due to adverse event before first tumor assessment).

[‡]Proportion of patients with confirmed CR, PR, or SD assessed by BICR.

CR, complete response; NE, not estimable; PD, progressive disease; PR, partial response; SD, stable disease; TTIR, time to initial response.


Response by BCIR

90-Day Follow Up for T-DXd 5.4 mg/kg

Response	Prespecified Early Cohort T-DXd 5.4 mg/kg (n = 52)		
	Data cutoff: March 24, 2022	Data cutoff: June 22, 2022	
Confirmed ORR,* % (95% CI) CR, % PR, %	53.8 (39.5-67.8) 1.9 51.9	57.7 (43.2-71.3) 1.9 55.8	
Median DoR,† mo (95% CI)	NE (4.2-NE)	8.7 (7.1-NE)	


- Median DoR was reached with the additional follow-up response analysis
- Confirmed ORR by BICR continued to demonstrate strong and clinically meaningful antitumor activity

Best Percent Change in Tumor Size by BICR




T-DXd 5.4 mg/kg (n = 52)

T-DXd 6.4 mg/kg (n = 28)



Safety



Adjudicated Drug-Related ILD in Safety Analysis Set

Adjudicated Drug-Related ILDs*	T-DXd 5.4 mg/kg (n = 101)	T-DXd 6.4 mg/kg (n = 50)
Any grade, n (%)	6 (5.9)	7 (14.0)
Grade 1	3 (3.0)	1 (2.0)
Grade 2	2 (2.0)	6 (12.0)
Grade 3 [†]	1 (1.0)	0
Grade 4	0	0
Grade 5 [†]	0	0
Cases resolved, n (%)	3 (50.0)	1 (14.3)
Median time to onset of first adjudicated ILD, days (range)	67.5 (40-207)	41.0 (36-208)

*Cases of potential ILD or pneumonitis were evaluated via independent adjudication committee. Data reported are for cases that were deemed drug related by ILD adjudication committee. [†]In safety analysis set, 1 investigator reported grade 3 for 5.4-mg/kg dose, and 1 investigator reported grade 5 ILD with 6.4-mg/kg dose were pending adjudication at data cutoff and were later adjudicated as grade 2 and grade 5 ILD, respectively.

The rate of adjudicated drug-related ILD was lower in the 5.4 mg/kg arm compared with the 6.4 mg/kg arm

Most cases of adjudicated drug-related ILD were low grade (grade 1/2); there were no Grade 4 or Grade 5 events



- At interim analysis, trastuzumab deruxtecan at 5.4 mg/kg provided clinically meaningful responses for HER2m NSCLC patients in the 2L+ setting
 - 57.7% confirmed ORR by BICR (n=30/52; 95% CI: 43.2, 71.3) 1.9% CR (n=1) + 55.8% PR (n=29)
 - 8.7 months median DOR (n=30; 95% CI: 7.1, NE)
- No new safety concerns; consistent with established safety profile of T-DXd
 - More favorable safety profile and lower incidence of ILD in the 5.4 mg/kg arm compared to 6.4 mg/kg arm
 - Early detection of and monitoring for ILD remains important for management

Trastuzumab deruxtecan (at 5.4 mg/kg) should be considered as a new standard of care for patients previously treated for HER2-mutant NSCLC

More to come...



2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPICS-02
- MONARCH 3
- SOLO1
- PAOLA-1

Lung Cancer

- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate-816
- NADIM II[‡]
- IMpower010[‡]

GU/GI and Other Cancer

- NICHE-2*
- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- EXPLORER/PATHFINDER

* ESMO Presidential Symposium ⁺ WCLC 2022




Does neoadjuvant nivo plus platinum-doublet chemotherapy provide benefit for patients with resectable NSCLC regardless of lymph node involvement?

Post hoc analysis

On <u>March 4 2022</u>, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the <u>neoadjuvant</u> setting. This represents the first FDA approval for neoadjuvant therapy for early-stage NSCLC.



Study Design: Randomized, open-label phase III trial neoadjuvant nivolumab + platinum chemotherapy for resectable Stage IB-IIIA NSCLC



Arm evaluating nivolumab (3 mg/kg for 3 cycles) + ipilimumab (1 mg/kg for 1 cycle) not shown.

Primary endpoints: pCR (by BIPR), EFS (by BICR)
Key secondary endpoints: OS, MPR (by BIPR), time to death or distant metastasis
Key exploratory endpoints: ORR (by BICR), surgery feasibility, peri/postoperative surgery-related AEs

⁺Vinorelbine + cisplatin, docetaxel + cisplatin, gemcitabine + cisplatin, pemetrexed + cisplatin, or paclitaxel + carboplatin

Data cutoff: October 20, 2021; median follow up: 29.5 months


Primary Endpoints

Neoadjuvant nivo plus platinum-doublet chemotherapy results in significant improvements compared with chemotherapy alone


- Statistically significant improvement in EFS over chemotherapy alone with a 37% reduction in the risk of progression, recurrence or death (HR 0.63; 95% CI: 0.45 to 0.87; P=0.0052)
- pCR rate **24**% vs 2.2%
- Depth of pathological response (low % residual viable tumor [RVT]) was associated with improved EFS outcomes with neoadjuvant NIVO + chemo

Key Secondary Endpoint

• Overall survival (OS): HR=0.57 (95% CI: 0.38–0.87); OS data were immature at the pre-specified interim analysis, and did not cross the boundary for statistical significance




EFS in patients with or without pathologic evidence of LN involvement



ESMO 2022. Abstr LBA50.

EFS by %RVT in patients with LN involvement^a: Nivo + CT



^aLN involvement refers to pathologic evidence of LN disease at resection that had or had not fully regressed after neoadjuvant treatment (0% or > 0% RVT in the resected LN). ^bPatients in the chemo arm with 0% RVT in both PT + LN, 1% (1/74); PT alone, 1% (1/74); LN alone, 4% (3/74); either PT or LN, 5% (4/74); > 0% RVT in PT + LN, 93% (69/74). ^cHRs were not computed because of the low number of events in the 0% RVT subgroups. 95% CI: d57–99, e42–91,f32–64



- Post hoc analysis revealed that patients with resectable NSCLC had improved EFS and pCR with neoadjuvant nivo + CT compared to CT alone regardless of pathologic evidence of LN involvement
- Greatest EFS achieved in patients treated with neoadjuvant nivolumab + CT with 0% RVT in both primary tumor and LN (vs those with 0% RVT in either LN or primary tumor, or those with >0% RVT)
- The % regression (area of immune-mediated tumor clearance) and % RVT for nivo + CT were inversely correlated and was predictive of EFS at 2 yr regardless of LN involvement

Neoadjuvant nivolumab in combination with platinumdoublet chemotherapy benefits patients with early stage NSCLC regardless of LN involvement and should be considered as a standard of care

Improves the chance of successful surgical treatment and reduces the risk of recurrence



2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPICS-02
- MONARCH 3
- SOLO1
- PAOLA-1

Lung Cancer

- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate-816
- NADIM II[†]
- IMpower010[‡]

GU/GI and Other Cancer

- NICHE-2*
- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- EXPLORER/PATHFINDER

* ESMO Presidential Symposium ⁺ WCLC 2022



NADIM II


Interim analysis: PFS and OS results

Update from the IASLC 2022 World Conference on Lung Cancer



NADIM II

Study Design: open-label, randomized, two-arm, phase II, multi-center clinical trial



Primary endpoint: pCR **Secondary endpoints**: PFS, OS, and biomarker analysis


Median follow-up time: 21.9 months Data cutoff: March 2021

© 2022 Cornerstone Specialty Network. All rights reserved.


WCLC2022 Absrt PL03.12 (Plenary 3: Presidential Symposium)

Secondary Endpoints

- PFS at 24 months was 66.6% for patients treated with nivolumab plus chemotherapy versus 42.3% for patients treated with chemotherapy
- Median PFS not reached in nivo + CT arm
- HR 0.48



- OS at 24 months was 84.7% for patients treated with nivolumab plus chemotherapy versus 63.4% for patients treated with chemotherapy
- Median OS not reached in either arm
- HR 0.40





NADIM II

- The first trial to show improved OS with a neoadjuvant immunotherapy-based combination for patients with resectable stage IIIA–B NSCLC
- PFS and OS improved and sustained with nivo + CT compared to chemo alone
 - PFS rate: 12 mo, 89.3% vs 60.7%; 24 mo, 66.6% vs 42.3%
 - OS rate: 12 mo, 98.2% vs 82.1%; 24 mo, 84.7% vs 63.4%

NADIM II supports the results of CheckMate-816

CheckMate-816


- Overall survival (OS): HR=0.57 (95% CI: 0.38–0.87); OS data were immature at the pre-specified interim analysis, and did not cross the boundary for statistical significance
- 24 mo OS rate, 83% with nivo + chemo vs 71% with chemo alone

Interim analysis: OS results

Update from the IASLC 2022 World Conference on Lung Cancer



Study Design: randomized, open-label Phase III



Primary endpoint: hierarchical evaluation of investigator-assessed DFS in 3 populations: stage II-IIIA with PD-L1 TC $\geq 1\%^{\dagger} \rightarrow all$ randomized stage II-IIIA \rightarrow ITT population (stage IB-IIIA)


Secondary endpoints: OS (in ITT if primary endpoints are positive); DFS in stage II-IIIA with PD-L1 TC ≥50%⁺; 3-yr, 5-yr DFS in all 3 populations; safety

Exploratory endpoints: OS biomarker analyses

Data cutoff for interim analysis: April 18, 2022 Median 46-mo follow-up

⁺PD-L1 SP264 IHC assay.

OS in Patients With Stage II-IIIA NSCLC and PD-L1 TC $\geq\!\!1\%$



No OS benefit observed in all-randomized stage II-IIIA or ITT (stage IA-III) patient populations


	All randomized stage II-IIIA		ITT (stage I-IIIA)	
	Atezo (n=442)	BSC (n=440)	Atezo (n=507)	BSC (n=498)
Events, n (%)	115 (26.0%)	116 (26.4%)	127 (25.0%)	124 (24.9%)
Median OS, mos	NR	NR	NR	NR
Stratified HR (95% CI)	0.95 (0.74 – 1.24)		0.995 (0.78 – 1.28)	
Stratified log- rank p value	NA		0.9661	

WCLC2022 Absrt PL03.09 (Plenary 3: Presidential Symposium)

OS by biomarker status

Subgroup (including	Atez	better BSC	better
<u>EGFR/ALK+)</u> PD-L1 status by SP263	<u>n</u>		HR (95% CI)
TC $\geq 1\%$	476	⊢ ♣-∮	0.71 (0.49-1.03)
TC ≥ 50%	229		0.43 (0.24-0.78)
TC 1%-49%	247	⊢ ∳ ⊣	0.95 (0.59-1.54)
TC < 1%	383	₽	1.36 (0.93-1.99)
	0.1	1.0	10.0
<u>Subgroup (excluding</u> <u>EGFR/ALK+)</u> PD-L1 status by SP263	<u>n</u>	I	<u>HR (95% CI)</u>
TC ≥ 1%	410	⊨♠⊣	0.67 (0.45-0.98)
TC ≥ 50%	209		0.42 (0.23-0.78)
TC 1%-49%	201	⊢- ∮ -1	0.93 (0.56-1.56)
TC < 1%	312	⊢ ∳⊣	1.21 (0.80-1.85)
	0.1	1.0	10.0

OS in Patients With Stage II-IIIA NSCLC and PD-L1 TC ≥50% excluding *EGFR/ALK*+



BSC 103101 98 96 95 92 90 87 84 80 77 76 75 71 64 52 45 35 24 14 8 4 3 2 NE



- In prespecified interim analysis of OS from phase III IMpower010 trial, adjuvant atezolizumab following complete resection and adjuvant chemotherapy suggests trend toward OS benefit (HR: 0.71 [95% CI: 0.49-1.03]) in patients with stage II-IIIA NSCLC with PD-L1 TC ≥1% vs BSC
 - Trend toward OS benefit also seen in patients with stage II-IIIA NSCLC with PD-L1 TC ≥50%;
 - OS HR: 0.43 (95% CI: 0.24-0.78)
- OS data are not mature

2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPiCS-02
- MONARCH 3
- SOLO1

specialty network

corners

• PAOLA-1

Lung Cancer

- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate-816
- NADIM II[‡]
- IMpower010⁺

GU/GI and Other Cancer

- NICHE-2*
- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- EXPLORER/PATHFINDER

*ESMO Presidential Symposium [†]WCLC 2022



Does neoadjuvant immune checkpoint inhibition with nivo + ipi provide benefit for patients with locally advanced MMR-deficient colon cancer?

Previous data from NICHE-1 (n=32) showed that immune checkpoint blockade is highly effective in non-metastatic dMMR colon cancers

100% pathologic responses and 60% pathologic complete responses

Chalabi et. al, Nat Med 2020; Verschoor et. al, ASCO 2022



KEY DATA


NICHE-2

Study Design: Investigator-initiated, non-randomized multicenter[‡] study

⁺6 participating hospitals in the Netherlands

- Non-metastatic, previously untreated dMMR colon adenocarcinoma
- cT3 and/or N+ disease based on radiologic staging*
- No clinical signs of obstruction
- No clinical symptoms or radiologic suspicion of perforation
- No active autoimmune disease or other medical conditions requiring systemic steroid or immunosuppressive medications (N=112)

*Protocol revision October 2020 added a primary endpoint of 3-year DFS and a new cohort of 70 patients with at least T3 and/or N+ tumors Current data combine n=30 from original cohort with new dMMR cohort



Primary endpoints: Safety and feasibility, 3-year disease-free survival (DFS)

Secondary endpoints: Major and complete pathologic response rate in post-treatment surgical specimen, Circulating tumor DNA dynamics, Translational research (DNA, RNA sequencing, single-cell sequencing, multiplex imaging)

Safety and feasibility endpoint is considered successful if surgery is performed on time (no more than 2 weeks delay) in 95% of patients, at a power of 80% and a two-sided significance level of 0.025. Timely surgery in less than 85% of patients would be deemed unacceptable • Survival: 3-year DFS of 93% would be deemed successful, at a power of 80% and a two-sided significance level of 0.025 (one-sample log-rank test assuming 82% DFS in the historical control group) • 95 patients needed

Baseline Characteristics

Characteristic	Number at risk (%) of intention to treat population (n=112)	
Female sex, n (%)	65 (58%)	
Median age, yr (range)	60 (20 – 82)	
ECOG PS, n (%) • 0 • 1	97 (87%) 15 (13%)	
 Primary tumor location Right colon Left colon Transverse colon 	76 (68%) 19 (17%) 17 (15%)	
Lynch syndromeUnknown	35 (31%) 10 (9%)	

Characteristic	Number at risk (%) of intention to treat population (n=112)	
Radiologic Stage		
• /	14 (13%)	
Low risk III	15 (13%)	
High risk III	83 (74%)	
Radiologic T Stage		
• T2	17 (15%)	
• T3 + T3/4a	25 (22%)	
• T4a	39 (35%)	
• T4b 63% clinical T4a or T4b	31 (28%)	
Radiologic N Stage		
• N0	14 (13%)	
• N1	29 (26%)	
• N2	69 (62%)	
Radiologic high-risk with both T454 (48%)and N254 (48%)		

KEY DATA

Adverse Events

Most common grade 1-2 AEs were infusion reactions, dry mouth, hyper- or hypothyroidism, fatigue and flu-like symptoms

Immune-related Adverse Events (n=112)			
Patients with any AE68 (61%)			
Grade ≥3	4 (4%)		
	Grade 3	Grade 4	
Amylase increase	1	0	
Lipase increase	0	1	
Hepatitis	1	0	
• Myositis	1	0	
• Rash	1	0	
AEs leading to delay in surgery ≥ 2 (2%) 2 weeks			

Five events observed in 4 (4%) patients. Amylase and lipase increases were asymptomatic and resolved without intervention. Rash and hepatitis were treated with prednisone and resolved completely. Myositis was treated with prednisone and mycophenolate and has resolved completely.


Surgery-related Adverse Events (n=112)		
Any	24 (21%)	
Grade ≥3	15 (13%)	
Anastomotic leakage or wound infections	6 (5%)	

- All patients underwent surgery, with 100% R0 resections
 98% of patients underwent timely surgery, meeting the safety primary endpoint
- Median 5.4 weeks from first dose (nivolumab + ipilimumab) to surgery
- No new safety signals

NICHE-2

Major pathologic response in 95% of patients; 67% pCR

Pathologic Responses (RVT)	Patients n=107
Yes (≤50%)	106 (99%)
Major (≤10%)	102 (95%)
Complete (0%)	72 (67%)
Partial (10% - 50%)	4 (4%)
No (≥50%)	1 (1%)



Green bars = NICHE-1 cohort; Blue bars = NICHE-2 cohort


Adjuvant chemotherapy (CTx)

14 patients with ypN+ disease

- 3 patients received adjuvant CTx*
- 5 patients >70 years
- 6 patients refused
- * 1 non-responder, 1 partial responder and 1 MPR

Disease recurrence
With a median follow-up of 13.1 months (1.4 - 57.4),
there have been no disease recurrences

pCR rate	No pCR	pCR
Sporadic tumor (n=65)	27 (42%)	38 (58%)
Lynch Syndrome (n=32)	7 (22%)	25 (78%)



- Neoadjuvant immunotherapy, in the form of one dose of ipi and two doses of nivo within 6 weeks prior to surgery, resulted in major pathologic responses in 95% of patients, including 67% pathologic complete responses, with dMMR colon cancer
- Treatment is well-tolerated with only 4% grade 3-4 immune-related adverse events
- No disease recurrences to date
- 3-year disease-free survival data expected in 2023

Neoadjuvant immunotherapy (one dose of ipilimumab and two doses of nivolumab ≤6 weeks prior to surgery) has the potential to become standard of care for patients with dMMR colon cancer

More to come...



2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPiCS-02
- MONARCH 3
- SOLO1

specialty network

corners

• PAOLA-1

Lung Cancer

- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate-816
- NADIM II[‡]
- IMpower010⁺

GU/GI and Other Cancer

- NICHE-2*
- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- EXPLORER/PATHFINDER

*ESMO Presidential Symposium [†]WCLC 2022



Does duration of androgen deprivation therapy (ADT) with post-operative radiotherapy impact patients with prostate cancer?

Key Questions:

- Who should have ADT added to their radiotherapy?
- What is the optimal duration of ADT?




RADICALS-HD

Study Design: randomized, multicenter phase III trial

Inclusion: Due for post-op RT after radical prostatectomy for non-metastatic adenocarcinoma, Post-operative serum prostate-specific antigen (PSA) < 0.4 ng/mL
 Exclusion: Prior pelvic RT, Prior hormone therapy, metastatic disease, PSA > 5ng/ml

Key STHT = 6 months ADT LTHT = 24 months ADT



Primary endpoint of metastasis-free survival

Note: study start date Nov 2007 (standards of care have evolved during that time including particularly the imaging approaches employed). Additionally, hormonal treatments were not standardized and patients and investigators could choose which of the randomizations to participate in.

Baseline Characteristics: RT alone vs RT+STHT

	RT alone (n=737)	RT + STHT (n=743)
Age, median years (IQR)	66 (61 – 69)	66 (61 – 69)
PSA at randomization , median (IQR)	0.2 (0.1 – 0.4)	0.2 (0.1 – 0.4)
Stage		
T2	289 (40%)	305 (42%)
ТЗа	325 (44%)	303 (41%)
T3b/4	112 (16%)	128 (17%)
N+ve	25 (3%)	25 (3%)
Gleason		
≤7	654 (89%)	657 (89%)
8-10	83 (11%)	86 (12%)
Positive margins		
Present	452 (61%)	472 (64%)
Absent	285 (39%)	271 (36%)


Treatment: RT alone vs RT+STHT

	RT alone (n=737)	RT + STHT (n=743)	
RT timing			
Adjuvant	208 (28%)	215 (29%)	
Early salvage	529 (72%)	528 (71%)	
Planned RT schedule			
52.5Gy / 20f	215 (29%)	222 (30%)	
66.0Gy / 33f	510 (69%)	511 (69%)	
Other	12 (2%)	10 (1%)	
Planned RT target			
Prostate bed	700 (95%)	692 (93%)	
Prostate bed + Pelvic LN	37 (5%)	51 (7%)	
Planned hormone therapy			
LHRH	613 (83%)	624 (84%)	
Bicalutamide	124 (17%)	119 (16%)	

RT alone vs RT+STHT

	RT alone (n=737)	RT + STHT (n=743)
Metastases-Free Survival (MFS)		
Events	142	126
HR (95%CI)	0.89 (0.6	59 – 1.14)
P-value	0	.35
10yr event free	79%	80%
Freedom-from-distant metastases (FFDM)		
Events	79	65
HR (95%CI)	•	58 – 1.15)
P-value	0	.24
10yr event free	88%	90%
Overall Survival (OS)		
Events	98	92
HR (95%CI)	•	55 – 1.19)
P-value	-	.42
10yr event free	86%	85%
Time to Salvage Hormone Therapy		
Events	176	109
HR (95%CI)	0.54 (0.4	42 – 0.70)
P-value	-	0001
10yr event free	73%	82%
Note: HR < 1 favor RT+STHT	© 2022 Corn	erstone Specialty Net

 Short course ADT, compared with no ADT, <u>did not</u> meaningfully improve MFS



© 2022 Cornerstone Specialty Network. All rights reserved.

ESMO 2022. Abstr LBA9.

Note: predicted 10yr MFS = 80%

Baseline Characteristics: RT+STHT vs RT+LTHT

	RT + STHT (n=761)	RT + LTHT (n-=762)
Age, median years (IQR)	65 (60-69)	65 (61-69)
PSA at randomization , median (IQR)	0.2 (0.1-0.5)	0.2 (0.1-0.5)
Stage		
T2	206 (27%)	215 (29%)
ТЗа	327 (43%)	309 (41%)
T3b/4	226 (29%)	235 (31%)
N+ve	63 (8%)	66 (9%)
Gleason		
≤7	545 (72%)	543 (71%)
8-10	215 (28%)	219 (29%)
Positive margins		
Present	480 (63%)	484 (64%)
Absent	281 (37%)	278 (36%)

Treatment: RT+STHT vs RT+LTHT


	RT + STHT (n=761)	RT + LTHT (n=762)
RT timing		
Adjuvant	328 (43%)	325 (43%)
Early salvage	433 (57%)	437 (57%)
Planned RT schedule		
52.5Gy / 20f	145 (19%)	148 (19%)
66.0Gy / 33f	604 (79%)	600 (79%)
Other	11 (1%)	13 (2%)
Planned RT target		
Prostate bed	645 (85%)	642 (84%)
Prostate bed + Pelvic LN	115 (15%)	119 (16%)
Planned hormone therapy		
LHRH	640 (84%)	636 (84%)
Bicalutamide	119 (16%)	124 (16%)
LHRH antagonist	1 (<1%)	0 (0%)

RADICALS-HD: Short course ADT vs long course ADT

RT + STHT vs RT + LTHT

	RT + STHT (n=761)	RT + LTHT (n-=762)	
Metastases-Free Survival (MFS) Events HR (95%CI) P-value 10yr event free	174 139 0.77 (0.61 – 0.97) 0.03 72% 78%		
Freedom-from-distant metastases (FFDM) Events HR (95%CI) P-value 10yr event free	•	76 7 – 0.85) 002 88%	
Overall Survival Events HR (95%CI) P-value 10yr event free	•	100 66 – 1.17) 38 85%	
Time to Salvage Hormone Therapy Events HR (95%CI) P-value 10yr event free	•	157 59 – 0.91) .005 75%	

- Long course ADT, compared with short course ADT, <u>did</u> meaningfully improve MFS
- At 10 years:
 - MFS 72% with RT + short term ADT
 - MFS 78% with RT + long term ADT



Note: HR < 1 favor RT+LTHT

ESMO 2022. Abstr LBA9.

Note: predicted 10yr MFS = 75%



Safety: RTOG toxicity

Maximum Grade	RT alone	RT + STHT	RT + STHT	RT + LTHT
O – 2	612 (83%) <i>P</i> -valu	635 (85%) ue 0.25	650 (85%) <i>P</i> -val	615 (81%) ue 0.06
3	114 (16%)	90 (12%)	99 (13%)	138 (18%)
4	7 (1%)	10 (1%)	6 (1%)	4 (1%)

- No grade 5 events
- Most common grade 3+ adverse events reported within 2 years after randomization:
 - 6% Urethral stricture
 - 4% Hematuria



RADICALS-HD

- Long term (24 months) ADT when added to post-operative radiotherapy for prostate cancer improved metastasis-free survival compared to short course (6 months) ADT
 - Patients included in the none versus short-term ADT comparison had less aggressive disease than those in the short-term versus long-term ADT comparison
- Overall survival data immature

Some patients will benefit from either short-term ADT versus no ADT or from long-term ADT versus short-term ADT

Need to personalize therapy – consider a combination of clinical factors to determine addition and length of ADT



2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPiCS-02
- MONARCH 3
- SOLO1

specialty network

corners

• PAOLA-1

Lung Cancer

- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate-816
- NADIM II[‡]
- IMpower010⁺

GU/GI and Other Cancer

• NICHE-2*

- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- EXPLORER/PATHFINDER

*ESMO Presidential Symposium [†]WCLC 2022

Does nivolumab + ipilimumab in combination with a TKI (cabozntinib) provide benefit for patients with previously untreated advanced renal cell carcinoma of IMDC intermediate or poor-risk?


CABOMETYX (cabozntinib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC) as a monotherapy (CABOSUN), the only single-agent TKI with NCCN preferred recommendation in Category 2A: 1L intermediate-/poor-risk clear-cell aRCC; and for patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab (CheckMate-9ER)





Study Design: randomized, double-blind phase III trial

Stratified by IMDC risk and region



*One prior systemic adjuvant therapy allowed for completely resected RCC and if recurrence occurred ≥6 mo after last dose of adjuvant therapy; adjuvant PD-1 or PD-L1 inhibitor in combination with CTLA-4 inhibitor not permitted. *Nivolumab given for maximum of 2 yr.

[‡]Tumor assessment (RECIST v1.1) at Wk 10, then every 8 wk through 50 wk, then every

12 wk. [§]Discontinuation of 1 agent did not necessitate discontinuing all agents.

Primary endpoint: PFS per RECIST v1.1 by BIRC (analyzed after 249 events in PITT population [first 550 patients randomized]) Secondary endpoint: OS

Additional endpoints: ORR, DoR, safety

Median follow-up: ITT: 17.7 mo, PITT: 20.2 mo

PITT, progression-free survival ITT

ESMO 2022. Abstr LBA8.


Baseline Characteristics

Characteristic	Cabozantinib + Nivolumab + Ipilimumab (n = 428)	Placebo + Nivolumab + Ipilimumab (n = 427)
Median age, yr (range)	61 (19-85)	60 (28-87)
Male, %	76	73
 Region, % US, Canada, Europe, Australia, New Zealand Latin America, Asia 	65 35	65 35
IMDC intermediate/poor risk, %	75/25	75/25
 Tumor PD-L1 status, % <1% ≥1% Indeterminate/missing 	64 20 17	62 22 16

Characteristic	Cabozantinib + Nivolumab + Ipilimumab (n = 428)	Placebo + Nivolumab + Ipilimumab (n = 427)
Karnofsky PS 100 or 90/70 or 80, %	59/41	63/37
Prior nephrectomy, %	65	65
1/≥2 sites with target/nontarget lesions per BIRC, %	19/80	19/80
Most common target/nontarget metastatic sites per BIRC, %		
• Lung	68	71
• Lymph node	54	50
• Liver	20	19
• Bone	17	21



PFS per RECIST v1.1 by BIRC



Tumor Response

BIRC Analysis	Cabozantinib + Nivolumab + Ipilimumab (n = 276)	Placebo + Nivolumab + Ipilimumab (n = 274)
ORR, % (95% CI)	43 (37.2-49.2)	36 (30.1-41.8)
 Best overall response, n (%) • CR • PR 	7 (3) 112 (41)	9 (3) 89 (32)
 SD PD NE 	119 (43) 23 (8) 15 (5)	100 (36) 55 (20) 21 (8)
Disease control rate, %*	86	72
Median time to objective response, mo (range)	2.4 (1.5-17.1)	2.3 (1.9-16.8)
Median DoR, mo (95% CI)	NR (20.2-NE)	NR (NE-NE)


Tumor response per RECIST v1.1 by BIRC

*Disease control rate = complete response + partial response + stable disease

Data cut-off: Jan 31, 2022



PFS and ORR by IMDC Risk Group (PITT Population)



ORR: 45% (95% CI, 38.1–52.0) for Cabo+Nivo+Ipi vs 35% (95% CI, 28.6–42.0) for Pbo+Nivo+Ipi ORR: 37% (95% CI, 25.8–50.0) for Cabo+Nivo+Ipi vs 38% (95% CI, 26.2–50.7) for Pbo+Nivo+Ipi

> Date of the 249th PFS event: Aug 23, 2021 Data cut-off for ORR: Jan 31, 2022

PFS and ORR per RECIST v1.1 by BIRC. IMDC risk group is per IxRS

Treatment Exposure and Discontinuation

Parameter	Cabozantinib + Nivolumab + Ipilimumab (n = 426)	Placebo + Nivolumab + Ipilimumab (n = 424)
Median exposure to study treatment, mo (range)	10.9 (0.2-28.5)	10.3 (0.1-28.1)
Median average daily dose of Cabo or Pbo, mg (range)	23.2 (3.6-40.0)	36.1 (0.8-40.0)
Median number of Nivo infusions (range)	10 (1-27)	9 (1-27)
Doses of Ipi received, % 4 3 2 1 	58 13 22 7	73 14 7
• 2 • 1	22 7	7 6

Parameter	Cabozantinib + Nivolumab + Ipilimumab (n = 426)	Placebo + Nivolumab + Ipilimumab (n = 424)
Any dose hold due to AE, %	90	70
Any dose reduction of cabozantinib or placebo due to AE, %	54	20
Treatment-related AE leading to discontinuation, %		
Any study treatment	45	24
Cabo or Pbo	28	14
• Nivo	26	18
• Ipi	30	12
 All treatment components (due to same AE) 	12	5

PFS and ORR per RECIST v1.1 by BIRC. IMDC risk group is per IxRS

Date of the 249th PFS event: Aug 23, 2021 Data cut-off for ORR: Jan 31, 2022

Safety Summary

TRAEs, %		Cabozantinib + Nivolumab + Ipilimumab (n = 426)		Placebo + Nivolumab + Ipilimumab (n = 424)	
	Any Grade	Grade 3/4	Any Grade	Grade 3/4	
Any event occurring in ≥20% in either group	99	73	91	41	
 Alanine aminotransferase increased 	46	26	17	6	
 Aspartate aminotransferase increased 	44	20	16	5	
Diarrhea	41	4	18	3	
 Palmar–plantar erythrodysethesia 	28	3	4	0	
Hypothyroidism	24	<1	15	0	
Hypertension	23	8	5	2	
• Fatigue	22	2	21	1	
Lipase increased	22	9	13	6	
Amylase increased	20	5	12	2	
• Rash	20	2	20	1	
• Pruritis	20	0	26	<1	

• Grade 5 TRAEs:

• ≤30 days after last dose: 3 patients (1%) in cabozantinib + nivolumab + ipilimumab arm (gastrointestinal hemorrhage, hepatic failure, respiratory failure) and 3 patients (1%) in placebo + nivolumab + ipilimumab arm (renal failure, myocarditis, sudden death)

- Through 100 days after last dose: 2 patients in cabozantinib + nivolumab + ipilimumab arm (immune-mediated hepatitis and hepatic failure) and 1 patient in placebo + nivolumab + ipilimumab arm (perforated ulcer)
- 58% and 35% of patients in cabozantinib + nivolumab + ipilimumab vs placebo + nivolumab + ipilimumab arms, respectively, used high-dose corticosteroids (≥40 mg of prednisone or equivalent) for AEs

- The triplet combination of cabozantinib with nivolumab plus ipilimumab demonstrated a significant benefit in PFS for previously untreated patients with advanced RCC of IMDC intermediate or poor risk versus the doublet of nivolumab and ipilmumab
 - The first study to use an immuno-oncology doublet standard of care as the control group
 - Subgroup analysis were consistent with greater benefit in the cabozantinib with nivolumab plus ipilimumab arm
 - Benefit greater for IMDC intermediate vs poor risk
- Improved ORR and disease control rate with cabozantinib with nivolumab plus ipilimumab
- Safety profile consistent with the individual treatment components; increase in some adverse events in the triplet versus the doublet as expected

The additional of cabozantinib to nivolumab and ipilimumab provided benefit in previously untreated patients with IMDC intermediate or poor risk advanced RCC

More to come...OS follow-up ongoing



2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPiCS-02
- MONARCH 3
- SOLO1

specialty network

corners

• PAOLA-1

Lung Cancer

- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate-816
- NADIM II[‡]
- IMpower010⁺

GU/GI and Other Cancer

- NICHE-2*
- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- EXPLORER/PATHFINDER

*ESMO Presidential Symposium [†]WCLC 2022



Does enfortumab vedotin with or without pembrolizumab provide benefit to 1L cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer?

Cohort K


On July 9, 2021, the FDA approved enfortumab vedotin-ejfv (Padcev) for adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 or programmed death-ligand inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy



KEY DATA

EV-103

Study Design: open-label, multiple cohort, phase Ib/2 study



Data cutoff: 10 Jun 2022

Primary endpoint: confirmed ORR by RECIST v1.1 per BICR

Secondary endpoints: confirmed ORR per RECIST v1.1 by investigator, DOR, DCR, PFS, OS, safety/ tolerability, and lab abnormalities

Exploratory endpoints: pharmacokinetics, antitherapeutic antibody, biomarkers of activity including baseline PD-L1 status and Nectin-4 expression, progression-free survival on subsequent therapy by investigator, patient reported outcomes Statistical considerations: The sample size was based on precision of the estimate for ORR characterized by 95%Cis; No formal statistical comparisons between the 2 treatment arms

Baseline Characteristics

Characteristic	Enfortumab Vedotin + Pembrolizumab (n = 76)	Enfortumab Vedotin (n = 73)
Male sex, n (%)	54 (71.1)	56 (76.7)
Median age, yr (range)	71 (51-91)	74 (56-89)
White race, n (%)	61 (80.3)	55 (75.3)
ECOG PS, n (%) • 0 • 1 • 2	33 (43.4) 33 (43.4) 10 (13.2)	28 (38.4) 35 (47.9) 10 (13.7)
Primary tumor locationLower tractUpper tract	46 (60.5) 30 (39.5)	51 (69.9) 21 (28.8)
Metastatic disease sites, n (%) Bone Liver Lung 	19 (25.0) 13 (17.1) 37 (48.7)	21 (28.8) 13 (17.8) 30 (41.1)

Characteristic	Enfortumab Vedotin + Pembrolizumab (n = 76)	Enfortumab Vedotin (n = 73)
Metastasis category, n (%) Lymph node only Visceral disease Not applicable* 	10 (13.2) 64 (84.2) 2 (2.6)	12 (16.4) 60 (82.2) 1 (1.4)
 PD-L1 status by CPS, n (%) <10 ≥10 Not evaluable 	44 (57.9) 31 (40.8) 1 (1.3)	38 (52.1) 28 (38.4) 7 (9.6)
 Meeting ≥1 Galsky criterion for cisplatin ineligibility, n (%)[†] CrCl < 60 and ≥30 mL/min¹ Grade ≥2 hearing loss ECOG PS 2 CrCl <60 and ≥30 mL/min¹ and grade ≥2 hearing loss CrCl <60 and ≥30 mL/min¹ and grade ≥2 hearing loss CrCl <60 and ≥30 mL/min¹ and ECOG PS 2 	76 (100) 48 (63.2) 11 (14.5) 6 (7.9) 7 (9.2) 4 (5.3)	72 (98.6) 44 (60.3) 11 (15.1) 9 (12.3) 7 (9.6) 1 (1.4)

Primary Endpoint: ORR by BICR

BICR Analysis	Enfortumab Vedotin + Pembrolizumab (n = 76)	Enfortumab Vedotin (n = 73)
Confirmed ORR, n (%)	49 (64.5)	33 (45.2)
• 95% CI	52.7 – 75.1	33.5 – 57.3
Best overall response, n (%) • CR • PR • SD • PD • NE • NA	8 (10.5) 41 (53.9) 17 (22.4) 6 (7.9) 3 (3.9) 1 (1.3)	3 (4.1) 30 (41.1) 25 (34.2) 7 (9.6) 5 (6.8) 3 (4.1)
Median time to objective response, mo (range)	2.07 (1.1-6.6)	2.07 (1.9-15.4)
Median number of treatment cycles (range)	11.0 (1-29)	8.0 (1-33)

Enfortumab Vedotin + Pembrolizumab


- 41/49 (85.7%) of responses observed at first assessment (week 9 ± 1 week)
- Confirmed ORRs were consistent across all prespecified subgroups
- 7/13 (53.8%) of confirmed ORRs observed in patients with liver metastases

Enfortumab Vedotin Monotherapy

• Activity is consistent with prior results in 2L+ la/mUC

EV-103

Maximum percent reduction from baseline of target lesion by BICR






KEY DATA

EV-103


DOR by BICR

	EV + P (n = 76)	EV (n = 73)
Responders, n	49	33
Progression events, n	13	14
mDOR (95% CI), months	NR (10.25 - NR)	13.2 (6.14 – 15.97)
DOR ≥ 12 months, %	65.4%	56.3%




PFS by BICR

	EV + P (n = 76)	EV (n = 73)
PFS events, n	31	38
mPFS (95% CI), months	NR (8.31 – NR)	8.0 (6.05 – 10.35)
PFS at 12 months, %	55.1%	35.8%



OS

	EV + P (n = 76)	EV (n = 73)
OS events, n	20	26
mOS (95% CI), months	22.3 (19.09 – NR)	21.7 (15.21 – NR)
OS at 12 months, %	80.7%	70.7%
Median follow-up time, months	14.8	15.0



EV-103

Treatment-related Adverse Events (TRAEs)

TRAEs in ≥20% of Patients, n (%)	Enfortumab Vedotin + Pembrolizumab (n = 76)		Enfortumab Vedotin (n = 73)	
	Any Grade	Grade ≥3	Any Grade	Grade ≥3
Overall	76 (100.0)	48 (63.2)	68 (93.2)	35 (47.9)
Fatigue	43 (56.6)	7 (9.2)	29 (39.7)	6 (8.2)
 Peripheral Sensory Neuropathy 	39 (51.3)	1 (1.3)	32 (43.8)	2 (2.7)
Alopecia	35 (46.1)	0	26 (35.6)	0
 Maculopapular rash 	35 (46.1)	13 (17.1)	21 (28.8)	1 (1.4)
Pruritis	30 (39.5)	3 (3.9)	19 (26.0)	1 (1.4)
Dysgeusia	23 (30.3)	0	25 (34.2)	0
 Weight decreased 	23 (30.3)	3 (3.9)	21 (28.8)	1 (1.4)
Diarrhea	22 (28.9)	5 (6.6)	20 (27.4)	4 (5.5)
 Decreased appetite 	20 (26.3)	0	28 (38.4)	0
Nausea	19 (25.0)	0	25 (34.2)	1 (1.4)
• Dry eye	15 (19.7)	0	8 (11.0)	0

No new safety signals observed: mostly grade 1 or 2

Serious TRAEs

- EV + P: 18 (23.7%)
- EV: 11 (15.1%)

TRAEs leading to death, per investigator

- EV + P: 3 (3.9%)
 - Pneumonitis, respiratory failure, sepsis
- EV: 2 (2.7%)
 - Multiple organ dysfunction, respiratory failure

KEY DATA

TRAEs of Special Interest* With EV

AE, n (%)	EV + P (n = 76)		EV (n = 73)	
AC, II (//)	Any Grade	Any Grade Grade ≥3		Grade ≥3
Skin reactions	51 (67.1)	16 (21.1)	33 (45.2)	6 (8.2)
Peripheral neuropathy	46 (60.5)	2 (2.6)	40 (54.8)	2 (2.7)
Ocular disorders Dry eye Blurred vision Corneal disorders 	20 (26.3) 18 (23.7) 9 (11.8) 0	0 0 0 0	21 (28.8) 9 (12.3) 10 (13.7) 4 (5.5)	0 0 0 0
Hyperglycemia	11 (14.5)	5 (6.6)	8 (11.0)	7 (9.6)
Infusion-related reactions	3 (3.9)	0	4 (5.5)	0

Note: *Differences in rates of skin reactions with enfortumab vedotin treatment-related AESIs and pembrolizumab TEAEs of special interest due to using different reporting methodologies developed for these agents.

TEAEs of Special Interest With Pembro

	EV + P(n = 76)		
TEAE, n (%)	Any Grade	Grade ≥3	
Severe skin reactions	21 (27.6)	15 (19.7)	
Hypothyroidism	10 (13.2)	0	
Pneumonitis	7 (9.2)	4 (5.3)	
Adrenal insufficiency	3 (3.9)	0	
Colitis	3 (3.9)	1 (1.3)	
Hyperthyroidism	3 (3.9)	0	
Infusion reactions	3 (3.9)	0	
Hepatitis	2 (2.6)	2 (2.6)	
Myasthenic syndrome	2 (2.6)	2 (2.6)	
Myositis	2 (2.6)	0	
Pancreatitis	2 (2.6)	1 (1.3)	
Hypophysitis	1 (1.3)	0	
Myocarditis	1 (1.3)	0	
Nephritis	1 (1.3)	1 (1.3)	
Thyroiditis	1 (1.3)	0	

SUMMARY

EV-103

- Enfortumab vedotin + pembrolizumab showed promising activity in 1L cisplatin ineligible patients with la/mUC
- ORR by BICR: 64.5%
- Median DOR not reached
- PFS and OS expected to continue to evolve
- No new safety concerns emerged
 - Safety profile for EV+P was manageable, including skin reactions and peripheral neuropathy

Enfortumab vedotin in combination with pembrolizumab has the potential to become a 1L treatment option for patients with la/mUC

More to come...



2022 ESMO Key Studies

Breast and Gynecological Cancer

- TROPiCS-02
- MONARCH 3
- SOLO1

cornerstone

specialty network

• PAOLA-1

Lung Cancer

- CodeBreaK 200*
- IPSOS*
- DESTINY-Lung02
- CheckMate-816
- NADIM II[‡]
- IMpower010⁺

GU/GI and Other Cancer

- NICHE-2*
- RADICALS-HD*
- COSMIC-313*
- EV-103 K
- **EXPLORER/PATHFINDER**

*ESMO Presidential Symposium [†]WCLC 2022



Does avapritinib benefit patients with advanced Systemic Mastocytosis (SM)?

Advanced systemic mastocytosis (AdvSM) is a rare myeloproliferative neoplasm commonly distinguished by the accumulation of neoplastic mast cells in bone marrow and other tissues and organs The majority (>90%) of patients with AdvSM harbor the KIT D816V mutation

On June 16, 2021, the Food and Drug Administration approved avapritinib (Ayvakit[™]) for adult patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL)



In

Excl

Reiter A, et al. Efficacy of Avapritinib versus Best Available

Therapy for AdvSM. Leukemia. Published Online 2022.

EXPLORER/PATHFINDER

Study Design: Multicenter, observational and retrospective study

Real-world patients treated with best available therapy (BAT) were identified based on inclusion and exclusion criteria similar to those from EXPLORER and PATHFINDER single-arm trials.

clusion criteria Adults (aged ≥18 years) with a diagnosis of AdvSM and documented subtype in their chart	Avapritinib arm N = 176 Data source: clinical studies		Comparative analyses of clinical outcomes N = 317 patients Primary endpoint
(ASM, SM-AHN, or MCL) Received ≥1 line of systemic therapy (not necessarily as first line) for	EXPLORER & PATHFINDER		 Overall survival Secondary endpoints
AdvSM at a participating site on or after January 1, 2009 The date of initiation of each line of therapy at the participating site was defined as the index date Had an index date ≥3 months prior to the start of data collection, unless earlier death	Populations Poole External control arm Best available therapy (BAT) N = 141	ed for Analysis	 Duration of treatment Time to next treatment line Change in serum tryptase concentration Safety (adverse events resulting in treatment modification or discontinuation, hospitalization, or death) Exploratory endpoints
usion History of another primary malignancy that was diagnosed or required therapy within 3 years before the index date (excluding completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma <i>in situ</i> in any site) Received avapritinib as the first therapy for AdvSM at a participating site	Data source: retrospective chart review conducted in multiple clinical sites		 Overall response rate, time to response, duration of response, progression-free survival, pure pathologic response

EXPLORER/PATHFINDER

Baseline Characteristics

	IPTW-weighted sample		
	Avapritinib	BAT	Standardized Difference ¹
Number of unique patients	Effective N = 172	Effective N = 134 ²	
Number of lines of therapy	Effective N = 172	Effective N = 210	
Age (years), mean (SD)	66.4 (10.5)	65.3 (12.4)	9.2%
Male, n (%)	60.0%	62.6%	5.3%
ECOG category, n (%)			
0	16.3%	19.2%	7.4%
1	59.0%	56.2%	5.8%
≥2	24.6%	24.7%	0.1%
Anemia, n (%)	55.4%	57.8%	5.0%
Thrombocytopenia, n (%)	38.9%	43.9%	10.2%*
AdvSM subtype diagnosis, n (%)			
SM-AHN	58.4%	58.2%	0.5%
ASM	26.5%	25.2%	3.0%
MCL	15.1%	16.6%	4.3%
Any skin involvement, n (%)	30.3%	32.5%	4.8%
Leukocyte count ≥16 × 10º/L, n (%)	18.5%	19.8%	3.3%
Serum tryptase¹⁰ ≥125 ng/mL, n (%)	72.5%	71.0%	3.2%
SRSF2/ASXL1/RUNX1 (S/A/R) mutation panel testing	100% of patients tested	70.8% of patients tested	
Number of mutated genes within panel, n (%) 0	55.3%	26.7%	
1	28.7%	30.1%	3.1%
≥2	16.0%	13.9%	5.8%
Number of prior lines of systemic therapy received			
0	47.2%	50.4%	6.4%
1	33.1%	32.4%	1.5%
2	14.6%	12.6%	5.6%
≥3	5.1%	4.6%	2.7%
Prior treatments received, n (%)			
TKI therapy	37.1%	29.9%	15.2%*
Cytotoxic therapy	20.1%	22.1%	4.8%
Biologic or other systemic therapy	14.9%	15.2%	0.7%

Reiter A, et al. Efficacy of Avapritinib versus Best Available	j
Therapy for AdvSM. Leukemia. Published Online 2022.	

© 2022 Cornerstone Specialty Network. All rights reserved.

Unweighted BAT sample	
Number of unique patients	N = 141
Number of lines of therapy	N = 222
Agents used in each included line of therapy, ¹ n (%)	
TKI therapy	120 (54.1%)
Cytotoxic therapy	91 (41.0%)
Biologic therapy	25 (11.3%)
Agent-level information available ¹	N = 196
ТКІ	
Midostaurin	99 (50.5%)
Dasatinib	2 (1.0%)
Ibrutinib	3 (1.5%)
Imatinib	2 (1.0%)
Ripretinib	4 (2.0%)
Cytotoxic therapy	
Cladribine	49 (25.0%)
Azacitidine	3 (1.5%)
Hydroxyurea	17 (8.7%)
Biologic	
Brentuximab vedotin	4 (2.0%)
Gemtuzumab ozogamicin	1 (0.5%)
Interferon-alpha	11 (5.6%)
Pegylated interferon	8 (4.1%)

KIT mutation


- Patients tested, n (%): Avapritinib vs BAT
 - 170 (96.6%) vs 140 (99.3%)
- Tested positive for KIT D816V, n (%): Avapritinib vs BAT
 - 156 (91.8%) vs 128 (91.4%)

Abbreviations: ASM, aggressive mastocytosis; ECOG, Eastern Cooperative Oncology Group; IPTW, inverse probability of treatment weighting; MCL, mast cell leukemia; SD, standard deviation; SM-AHN, systemic mastocytosis with an associated hematologic neoplasm, TKI, tyrosine-kinase inhibitor.

Notes:

- 1. A standardized difference of greater than 10% indicates meaningful imbalance between the two cohorts even after IPTW, denoted by a star (
- 2. Real-world patients with unknown ECOG score were excluded (N=20).

Primary Endpoint: Overall Survival



Overall Survival (OS) weighted by IPTW	Avapritinib	BAT	
Number of unique patients	Effective N=172	Effective N=136	
Number of lines of therapy	Effective N=172	Effective N=210	
Median OS, months (95% CI)	49.0 (46.9, NE)	26.8 (18.2, 39.7)	
Adjusted HR (95% CI)	0.48 (0.29, 0.79)		
p value	0.004*		

OS rates were higher among avapritinib patients at all time points:


- 6 months: 96.4% vs. 84.8%
- 12 months: 86.4% vs. 73.8%
- 24 months: 74.6% vs. 50.9%
- 36 months: 68.0% vs. 42.7%
- 48 months: 61.9% vs. 30.0%

Reiter A, et al. Efficacy of Avapritinib versus Best Available Therapy for AdvSM. Leukemia. Published Online 2022.

KEY DATA

EXPLORER/PATHFINDER

Adjusted OS rates were higher with avapritinib vs. BAT amongst pre-treated AdvSM patients




NR (NE, NE)

17.2 (14.6, 36.5)

0.37 (0.18, 0.75)

0.006

Adjusted OS rates were higher with avapritinib vs. BAT amongst AdvSM patients receiving 1st line therapies



Overall Survival (OS) weighted by IPTW	Avapritinib	ВАТ	
Number of unique patients	Effective N=62	Effective N=115	
Number of lines of therapy	Effective N=62	Effective N=115	
Mean follow-up time, months	17.8	26.1	
Median OS, months (95% CI)	49.0 (29.6, NE)	27.0 (19.7, 44.3)	
Adjusted HR (95% Cl)	0.40 (0.22, 0.74)		
p value	0.003		


Reiter A, et al. Efficacy of Avapritinib versus Best Available Therapy for AdvSM. Leukemia. Published Online 2022.

Median OS, months (95% CI)

Adjusted HR (95% CI)

p value

Duration of Treatment



Duration of Treatment (DOT) weighted by IPTW	Avapritinib	BAT	
Number of unique patients	Effective N=173	Effective N=131	
Number of lines of therapy	Effective N=173	Effective N=201	
Median DOT, months (95% CI)	23.8 (20.3, 40.9)	5.4 (5.0, 7.5)	
Adjusted HR (95% CI)	0.36 (0.26, 0.51)		
p value	<0.001*		


Rates of ongoing response were higher for the avapritinib cohort versus BAT cohort at all time points:

- 6 months: 85.6% vs. 45.0%
- 12 months: 67.7% vs. 32.5%
- 24 months: 48.8% vs. 16.1%
- 36 months: 34.7% vs. 11.1%
- 48 months: 24.7% vs. 8.2%

Reiter A, et al. Efficacy of Avapritinib versus Best Available Therapy for AdvSM. Leukemia. Published Online 2022.

EXPLORER/PATHFINDER

OS was significantly improved in Avapritinib vs. Midostaurin or Cladribine



Reiter A, et al. Efficacy of Avapritinib versus Best Available Therapy for AdvSM. Leukemia. Published Online 2022.

Reduction in serum tryptase levels

Maximum Reduction in Serum Tryptase Weighted by IPTW	Avapritinib	BAT
Number of unique patients	Effective N=173	Effective N=106
Number of lines of therapy	Effective N=173	Effective N=150
Absolute reduction	-278.4 (245.8)	-114.7 (245.1)
Percentage reduction	-87.1 (17.2)	-18.0 (123.9)
Adjusted mean difference in percentage change (95% CI)	-60.34 (-72.8	81 – -47.86)
p value	<0.0	01*
Time to maximum reduction, mean months	8.8	8.5

Abbreviations: CI, confidence interval; IPTW, inverse probability of treatment weighting; HR, hazard ratio.

[#] Negative values indicated reduction.

* p value less than 0.05.

Reiter A, et al. Efficacy of Avapritinib versus Best Available Therapy for AdvSM. Leukemia. Published Online 2022.



EXPLORER/PATHFINDER

- Patients with advanced SM treated with avapritinib (200 mg orally once daily) compared to patients treated with best available therapy experienced:
 - Significantly improved overall survival
 - Longer duration of treatment
 - Greater reductions in serum tryptase levels

- Monitor platelet counts
 - AYVAKIT is not recommended in patients with AdvSM with platelet counts < 50 X 10^9 /L
 - Supportive therapies recommended

Reiter A, et al. Efficacy of Avapritinib versus Best Available Therapy for AdvSM. Leukemia. Published Online 2022.

Avapritinib provides benefit to patients with advanced Systemic Mastocytosis and should be considered as standard of care

Need for high sensitivity diagnostic testing: KIT D816V assay

